ClinicalTrials.gg
RecruitingNCT07444593Updated Sep 14, 2026

Transverse Tibial Bone Transport (TTT) in the Management of Chronic Diabetic Lower Extremity Wounds

An interventional study of Biodynamik XT3 in Diabetic Foot Ulcer and Chronic Ulcers of the Lower Limb, sponsored by Biodynamik, Inc. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Biodynamik, Inc · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Planned enrollment
112th of 322
100 · median 60
Started
2026
with 13 others
No phase
186 of 381
38 open now
Primary completion
2027-07
later than 62 of 83 live
Registered
373rd of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 112th largest by planned enrollment of the 322 interventional ones that give a count, is one of 14 that started in 2026, is one of 186 with no phase, reaches primary completion later than 62 of the 83 other live ones, and was the 373rd registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and clinical performance of transverse tibial bone transport in patients with chronic ischemic and diabetic lower extremity ulcers. This study will assess wound healing outcomes and limb preservation in a population with limited therapeutic alternatives.

Read the detailed description

Diabetic lower extremity ulcers are associated with impaired blood flow, delayed wound healing, high morbidity, and an increased risk of limb loss. In some patients, conventional treatments such as wound care, revascularization procedures, or adjunctive therapies are ineffective or not feasible, leaving limited options short of major amputation.

Transverse tibial bone transport (TTT) is a surgical technique that applies controlled distraction to the tibial cortex and has been reported in prior clinical studies to stimulate angiogenesis, improve local perfusion, and support wound healing in ischemic conditions.

03

Conditions studied

  • Diabetic Foot Ulcer
  • Chronic Ulcers of the Lower Limb

Browse trials for

Keywords

  • Transverse Bone Transport
  • DFU
  • TTT
  • Biodynamik
  • XT3
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (>=22 years).
  • Chronic diabetic foot ulcer wound persisting >=12 weeks and less than 104 weeks to standard wound care.
  • Wound location within distal 1/3 tibia and below including foot.
  • Wound stages: WiFi >= 3
  • At least one patent lower extremity tibial vessel (after revascularization if needed).
  • Able to provide and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Active systemic infection (positive blood cultures)
  • Severe sepsis (2 out of 4 SIRS criteria with impact on organ dysfunction)
  • Subacute lower extremity wound \<12 weeks with or without standard wound cares
  • Internal hardware within 10cm of possible TTT placement
  • Most proximal aspect of wound within 10cm of most distal pin of possible TTT placement
  • End Stage Renal Disease requiring dialysis
  • Renal function values

    • : \<15ml/min and
    • Creatinine: >6mg/dL and
    • BUN: >50 mg/dL
  • Lab values of Serum albumin less than 2.5 g/dL or less than 8.0 g/dL or count less than 75,000/μL
  • Wounds less than 1 cm3 or greater than 30 cm3
  • Wounds that are circumferential as defined as a wound involving 360° of the limb circumference, with complete circumferential wounds defined as 360° involvement.
  • >10mg prednisone equivalent daily for >2 weeks
  • Patients with osteomyelitis in the ipsilateral tibia at planned corticotomy site
  • TNF-inhibitors or JAK inhibitors or chemotherapy-dose methotrexate
  • Cognitive or social limitations precluding consent or follow-up
  • Current participation in another study (drug or device)
  • (WBC \<4) or undergoing active chemotherapy
  • >10
  • \<18.5 kg/m2
  • Pregnant, lactating, or planning to become pregnant
  • Severe hepatic impairment defined by patient on a transplant list, MELD > 20 or Child's class C.
  • A history of conditions that may impair wound healing in the opinion of the Investigator, for example, disorders, renal failure patients on dialysis, or medications that impair the healing process.
  • Active local wound infection as defined by erythema greater than 0.5 cm from the wound margin AND at least one other localized sign of inflammation (purulent discharge, induration, localized warmth, or pain/tenderness)
  • less than 12 months
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • No intervention
    Standard of Care (control)

    Standard Wound Care

  • Experimental
    Standard Wound Care plus TTT

    Device: Biodynamik XT3

Interventions

  • DeviceBiodynamik XT3

    Application of XT3 system and transverse tibial bone transport procedure

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with wound closure

    To demonstrate the safety and effectiveness of the investigational procedure, when used in addition to standard wound care, in promoting clinically meaningful healing of chronic diabetic foot ulcers, specifically, to demonstrate that the proportion of subjects with wound closure is greater for the investigational procedure than standard wound care alone at 18 weeks while maintaining an acceptable safety profile. Proportion of subjects with wound closure as defined as 100% re-epithelialization of the target diabetic foot ulcer where there is no drainage or dressing is not required and confirmed at two consecutive study visits 2 weeks apart.

    Time frame: From enrollment to 18 weeks

Secondary outcomes

  1. Proportion of patients with PAR of greater than 60% at 8 and 18 weeks.

    The proportion of patients between each cohort who achieve a Percent Area Reduction of greater than 60%

    Time frame: At 8 and 18 weeks

  2. Mean PAR summarized at 8 and 18 weeks

    To compare mean Percent Area Reduction (PAR) between treatment groups at 8 and 18 weeks

    Time frame: From enrollment to 18 weeks

  3. Frequency of subsequent procedures

    Frequency of subsequent procedures (surgical debridement; minor/major amputation)

    Time frame: From enrollment to 18 weeks

  4. Time to achieve wound closure

    Compare the time to achieve wound closure at 18 weeks and through 12 months

    Time frame: Enrollment through 18 weeks and 12 months

  5. Vascular changes as measured by Ankle Brachial Index (ABI)

    ABI (No units; ratio) at 18 weeks and at 6, 9 and 12 months

    Time frame: From enrollment to 18 weeks, 6, 9 and 12 months

  6. Improvement in Visual Analog Scale to measure pain

    Improvement in pain as measured in a 10 point Visual Analogue Scale (VAS) at 8 and 18 weeks. VAS lowest score is 0 (no pain). While 10 is the highest score (worst pain).

    Time frame: From enrollment to 18 weeks

  7. Frequency of wound recurrence

    Frequency of wound recurrence/re-ulceration at 12 weeks and at 6, 9 and 12 months

    Time frame: Enrollment until 12 months

  8. Amputation free survival

    Amputation free survival at 12 weeks and at 6, 9 and 12 months

    Time frame: Enrollment until 12 months

  9. Vascular changes as measured by Transcutaneous Oxygen Pressure (TcPO2)

    TcPO2 (mmHG) at 6 weeks, 18 weeks and at 6, 9 and 12 months. Oxygen tension at the skin surface, reflecting tissue oxygenation and perfusion.

    Time frame: Measured at baseline to 18 weeks and through 12 months

  10. Improvement in Patient Reported Outcome Wound-QoL-17 at 18 weeks

    Improvement in Quality of Life Measure Wound-QoL-17 at 18 weeks. Score (0-4 mean or 0-68 total; Transformed score 0-100

    Time frame: From enrollment to 18 weeks

  11. Time to heal for surgical site

    Time to heal for pin sites, incision sites and bone consolidation

    Time frame: Enrollment to 18 weeks

Other outcomes

  1. Safety Endpoint - Adverse Events

    • Frequency of treatment-emergent serious and non-serious adverse events

    Time frame: Enrollment to 18 weeks

  2. Safety endpoint - TTT Related

    Frequency of device-related adverse events in the TTT arm including pin site infection and device breakage

    Time frame: Enrollment to 18 weeks

  3. Plasma growth factor level changes as measured by VEGf at 18 weeks and at 6,9 and 12 months

    Vascular Endothelial Growth Factor) measured in either picograms per milliliter (pg/mL) or nanograms per liter (ng/L) in serum or plasma

    Time frame: From enrollment until 12 months

  4. Vascular Perfusion measured by Computed Tomography Angiogram (CTA) at 18 weeks and at 6, 9 and 12 months

    CTA is measured in Hounsfield Units (HU)

    Time frame: Through 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Nie X, Kuang X, Liu G, Zhong Z, Ding Y, Yu J, Liu J, Li S, He L, Su H, Qin W, Zhao J, Hua Q, Chen Y. Tibial cortex transverse transport facilitating healing in patients with recalcitrant non-diabetic leg ulcers. J Orthop Translat. 2020 Dec 9;27:1-7. doi: 10.1016/j.jot.2020.11.001. eCollection 2021 Mar. PubMed 33344165 ↗
  • Chen Y, Kuang X, Zhou J, Zhen P, Zeng Z, Lin Z, Gao W, He L, Ding Y, Liu G, Qiu S, Qin A, Lu W, Lao S, Zhao J, Hua Q. Proximal Tibial Cortex Transverse Distraction Facilitating Healing and Limb Salvage in Severe and Recalcitrant Diabetic Foot Ulcers. Clin Orthop Relat Res. 2020 Apr;478(4):836-851. doi: 10.1097/CORR.0000000000001075. PubMed 31794478 ↗
  • Luxon A, Syziu A, Harrison WD, Islam A, Mason L. A Systematic Review on Tibial Cortex Transverse Transport in the Treatment of Ischemic Ulcers of the Lower Limb. Foot Ankle Int. 2025 Aug;46(8):914-924. doi: 10.1177/10711007251341312. Epub 2025 Jun 26. PubMed 40567177 ↗
  • Chen Y, Ding X, Zhu Y, Jia Z, Qi Y, Chen M, Lu J, Kuang X, Zhou J, Su Y, Zhao Y, Lu W, Zhao J, Hua Q. Effect of tibial cortex transverse transport in patients with recalcitrant diabetic foot ulcers: A prospective multicenter cohort study. J Orthop Translat. 2022 Oct 12;36:194-204. doi: 10.1016/j.jot.2022.09.002. eCollection 2022 Sep. PubMed 36263383 ↗
  • Ding Y, Yu D, Huang H, Peng X, Yang S, Lin Z, Zhou P, Liang J, Zou X, Mo R, Pan K, Zheng P, Kuang X, Nie X, Hua Q. Combining Tibial Cortex Transverse Transport (TTT) and Endovascular Therapy (EVT) for Limb Salvage in Chronic Limb-Threatening Ischemia. Orthop Surg. 2024 Sep;16(9):2132-2139. doi: 10.1111/os.14222. Epub 2024 Sep 7. PubMed 39243174 ↗
  • Liao MM, Zhang F, Wang YK, Wang MW, Cao JR, Jin ZH, Ren YJ, Chen S. Transverse tibial bone transport promotes distraction osteogenesis and improves blood flow in the management of diabetic foot. World J Diabetes. 2026 Jan 15;17(1):111847. doi: 10.4239/wjd.v17.i1.111847. PubMed 41608106 ↗
  • Ou S, Xu C, Yang Y, Chen Y, Li W, Lu H, Li G, Sun H, Qi Y. Transverse Tibial Bone Transport Enhances Distraction Osteogenesis and Vascularization in the Treatment of Diabetic Foot. Orthop Surg. 2022 Sep;14(9):2170-2179. doi: 10.1111/os.13416. Epub 2022 Aug 10. PubMed 35946439 ↗
  • Hu XX, Xiu ZZ, Li GC, Zhang JY, Shu LJ, Chen Z, Li H, Zou QF, Zhou Q. Effectiveness of transverse tibial bone transport in treatment of diabetic foot ulcer: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023 Jan 4;13:1095361. doi: 10.3389/fendo.2022.1095361. eCollection 2022. PubMed 36686461 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jul 2027, 10 months later.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 10 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 3, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07444593
Lead sponsor
Biodynamik, Inc
Collaborators
Mayo Clinic
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Elizabeth Wellings, MD
Contact
Wellings.elizabeth@mayo.edu
9049532496
Lauren Evans
Contact
evans.lauren2@mayo.edu
Elizabeth Wellings
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion